Shuttle Pharmaceuticals dismisses Forvis Mazars as auditor; no successor engaged

Shuttle Pharmaceuticals Holdings, Inc.

Audit Committee and Board approved dismissal on Oct. 16, 2026, effective after the Q3 2026 Form 10-Q for the quarter ended Sept. 30, 2026.
Forvis Mazars' FY2025 and FY2024 reports had no adverse opinion or disclaimer and were not qualified, but included a going-concern explanatory paragraph.
No disagreements; reportable events limited to material weaknesses in accounting policies/close oversight, review and segregation of duties over journal entries/spreadsheets.
Other weaknesses: ITGC super-user access and segregation-of-duties issues; entity-level controls over timely communication of material contracts; insufficient technical accounting/valuation expertise.
As of the Oct. 22, 2026 filing, no replacement independent auditor had been engaged; Audit Committee authorized Forvis to respond to successor inquiries.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.